跳至主要内容
临床试验/NCT04390074
NCT04390074已完成不适用

COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality

Uppsala University1 个研究点 分布在 1 个国家目标入组 9,905 人开始时间: 2020年5月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
9,905
试验地点
1
主要终点
Chronic medications as risk factor of intensive care for COVID-19

研究概览

简要总结

The Corona virus disease 2019 (COVID-19) pandemic is currently involving all parts of the world. Several risk factors for critical illness and death from the disease have been proposed. However, the observed associations between different comorbidities and chronic medications have not fully been related to the frequencies of the same comorbidities and chronic medications in age- and sex-matched controls from the general population. This is important since some of the proposed risk factors are very common in the aged who, by age alone, are more prone to a more severe course of the disease.

By combining several registries, we will compare, on several comorbidities such as hypertension and diabetes and several medications such as immunosuppressant drugs and Angiotensin Converting Enzyme (ACE)-inhibitors, the first 2000 cases of COVID-19 patients receiving critical care in Sweden to a set 8000 age- and sex-matched controls.

详细描述

The COVID-19 pandemic is currently involving all parts of the world. Several risk factors for critical illness and death from the disease have been proposed. However, the observed associations between different comorbidities and chronic medications have not fully been related to the frequencies of the same comorbidities and chronic medications in age- and sex-matched controls from the general population. This is important since some of the proposed risk factors are very common in the aged who, by age alone, are more prone to a more severe course of the disease.

By combining several registries, we will compare, on several comorbidities such as hypertension and diabetes and several medications such as immunosuppressant drugs and ACE-inhibitors, the first 2000 cases of COVID-19 patients receiving critical care in Sweden to a set 8000 age- and sex-matched controls.

Data sources:

Registries of the Swedish board of Health and wellfare:

  1. The patient registry containing information including diagnostic codes from all specialized Healthcare contacts in Sweden. Reporting i governed by law.
  2. The Swedish Prescribed Drug Register to which all dispensations from pharmacies of prescribed drugs are reported.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Included in the SIR with COVID-19 any time until data acquisition

排除标准

  • •Age below 18 years.

结局指标

主要结局

Chronic medications as risk factor of intensive care for COVID-19

时间窗: Drug dispensation within 6 months prior inclusion

Odds ratio of intensive care treated patients with COVID-19 having ongoing treatment with drugs blocking the Renin-Angiotensin-Aldosterone-System (RAAS), statins, immunosuppressant drugs, oral anticoagulant drugs, oral thrombocyte aggregation inhibitors or antiviral drugs.

Comorbidities as risk factor of intensive care for COVID-19

时间窗: 5 years prior to inclusion

Odds ratio of intensive care treated patients with COVID-19 having been diagnosed with diabetes typ I, diabetes type II, ischemic heart disease, other heart disease, cerebrovascular disease, cancer, chronic renal failure, chronic obstructive pulmonary disease (COPD) asthma, obesity, immunosuppressed disease or systemic inflammatory disease.

次要结局

  • Chronic medications as risk factor of death during intensive care for COVID-19(Drug dispensation within 6 months prior inclusion)
  • Comorbidities as risk factor of death during intensive care for COVID-19(5 years prior to inclusion)

研究者

发起方
Uppsala University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验